Kaigene

United States · Biotech

Kaigene develops antibody medicines for autoimmune diseases, targeting harmful antibodies and the cells that produce them.

Platforms

The company develops antibody discovery platforms and therapeutic programs aimed at modifying disease mechanisms. Its pipeline includes FcRn and APRIL targeted candidates.

Development

Kaigene is based in Rockville, Maryland. Its research and licensing partnerships support the development of medicines for severe autoimmune conditions.

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Equity offering$55MParticipants not disclosed
Sourceskaigene.com ↗